PLX4032: Does it keep its promise for metastatic melanoma treatment?

Expert Opinion on Investigational Drugs

Volumn 19, Issue 11, 2010, Pages 1439-1449

  Livingstone, Elisabeth ^a   Zimmer, Lisa ^a   Piel, Sarah ^a   Schadendorf, Dirk ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

BRAF inhibitor; cutaneous squamous cell carcinoma; MAPK pathway; melanoma; PLX4032; RAS RAF MEK ERK pathway; targeted therapy

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; B RAF KINASE; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CHIR 265; DACARBAZINE; FLUOROURACIL; GSK 2118436; HEAT SHOCK PROTEIN 90 INHIBITOR; INTERLEUKIN 2; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; OXALIPLATIN; PACLITAXEL; PLX 4032; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; RO 5185426; SORAFENIB; UNCLASSIFIED DRUG;

ALOPECIA; ANEMIA; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RESISTANCE; CLINICAL TRIAL; COLON CANCER; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED CANCER; DRUG MECHANISM; FATIGUE; GERM CELL TUMOR; HUMAN; KERATOACANTHOMA; MELANOMA; METASTASIS; MONOTHERAPY; NAUSEA; NONHUMAN; OVARY CANCER; OVERALL SURVIVAL; PANCYTOPENIA; PHOTOSENSITIVITY; PROGRESSION FREE SURVIVAL; PRURITUS; RECTUM CANCER; SIGNAL TRANSDUCTION; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; THYROID CANCER; TREATMENT DURATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; INDOLES; MELANOMA; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; SULFONAMIDES;

EID: 77958450196     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.527945     Document Type: Article

References (77)

1. How common is skin cancer? WHO, 2010. Available from: http://www.who int/uv/faq/skincancer/en/index1.html [Last accessed on 21 June 2010]
2. Linos E, Swetter SM, Cockburn MG, et al. Increasing burden of melanoma in the United States. J Invest Dermatol 2009;129(7):1666-74
3. Cancer Facts and Figures 2010. American Cancer Society, 2010. Available from: http://www.cancer.org/downloads/STT/Cancer-Facts-and-Figures-2010.pdf [Last accessed on 21 June 2010]
4. Balch CM, Gershenwald JE, Soong SJ, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199-206
5. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004;351(10):998-1012
6. Tawbi HA, Kirkwood JM. Management of metastatic melanoma. Semin Oncol 2007;34(6):532-45
7. Nashan D, Muller ML, Grabbe S, et al. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine. J Eur Acad Dermatol Venereol 2007;21(10):1305-18
8. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19(1):21-34
9. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010. [Epub ahead of print]
10. Garbe C, Schadendorf D, Stolz W, et al. Short German guidelines: malignant melanoma. J Dtsch Dermatol Ges 2008;6(Suppl 1):S9-14
11. Bishop JA, Corrie PG, Evans J, et al. UK guidelines for the management of cutaneous melanoma. Br J Plast Surg 2002;55(1):46-54
12. Coit DG, Andtbacka R, Bichakjian CK, et al. Melanoma. J Natl Compr Canc Netw 2009;7(3):250-75
13. Negrier S, Saiag P, Guillot B, et al. Clinical practice guideline: 2005 update of recommendations for the management of patients with cutaneous melanoma without distant metastases (summary report). Bull Cancer 2006;93(4):371-84
14. Skalicky SE, Holt PE, Giblin M, et al. Australian Cancer Network clinical practice guidelines for the management of ocular and periocular melanoma: an evidence-based literature analysis. Clin Experiment Ophthalmol 2008;36(7):646-58
15. Flaherty K, Puzanov I, Sosman J, et al. Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J Clin Oncol (Meeting Abstracts) 2009, 2009;27(15S):abstract.
16. Curtin JA, Fridlyand J, Kageshita T, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135-47
17. Meier F, Schittek B, Busch S, et al. The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma. Front Biosci 2005;10:2986-3001
18. Martin GS. Cell signaling and cancer. Cancer Cell 2003;4(3):167-74
19. Sala E, Mologni L, Truffa S, et al. BRAF silencing by short hairpin RNA or chemical blockade by PLX4032 leads to different responses in melanoma and thyroid carcinoma cells. Mol Cancer Res 2008;6(5):751-9
20. Zhuang L, Lee CS, Scolyer RA, et al. Activation of the extracellular signal regulated kinase (ERK) pathway in human melanoma. J Clin Pathol 2005;58(11):1163-9
21. Zhang XD, Borrow JM, Zhang XY, et al. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene 2003;22(19):2869-81
22. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949-54
23. Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63(14):3955-7
24. Cohen Y, Rosenbaum E, Begum S, et al. Exon 15 BRAF mutations are uncommon in melanomas arising in nonsun-exposed sites. Clin Cancer Res 2004;10(10):3444-7
25. Brose MS, Volpe P, Feldman M, et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002;62(23):6997-7000
26. Wan PT, Garnett MJ, Roe SM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116(6):855-67
27. Bhatt KV, Spofford LS, Aram G, et al. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling. Oncogene 2005;24(21):3459-71
28. Wellbrock C, Rana S, Paterson H, et al. Oncogenic BRAF regulates melanoma proliferation through the lineage specific factor MITF. PLoS ONE 2008;3(7):e2734
29. Hoeflich KP, Gray DC, Eby MT, et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006;66(2):999-1006
30. Sharma SV, Settleman J. Oncogene addiction: setting the stage for molecularly targeted cancer therapy. Genes Dev 2007;21(24):3214-31
31. Weinstein IB, Joe A. Oncogene addiction (discussion 80). Cancer Res 2008;68(9):3077-80
32. Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
33. Eisen T, Ahmad T, Flaherty KT, et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 2006;95(5):581-6
34. Egberts F, Kahler KC, Livingstone E, Hauschild A. Metastatic melanoma: scientific rationale for sorafenib treatment and clinical results. Onkologie 2008;31(7):398-403
35. Hauschild A, Agarwala SS, Trefzer U, et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J Clin Oncol 2009;27(17):2823-30
36. Schwartz GK, Robertson S, Shen A, et al. A phase I study ofXL281, a selective oral RAF kinase inhibitor in patients (Pts) with advanced solid tumors. J Clin Oncol 2009;27(15s Suppl):abstract 3513
37. Ramurthy S, Subramanian S, Aikawa M, et al. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors. J Med Chem 2008;51(22):7049-52
38. Stuart DD, Aardalen KM, Lorenzana EG, et al. Characterization of a novel Raf kinase inhibitor that causes target dependent tumor regression in human melanoma xenografts expressing mutant B-Raf. AACR Meeting Abstracts 2006;47(1140):abstract 4856
39. Amiri P, Aikawa ME, Dove J, et al. CHIR-265 is a potent selective inhibitor of c-Raf/B-Raf/mutB-Raf that effectively inhibits proliferation and survival of cancer cell lines with Ras/Raf pathway mutations. Proc Am Assoc Cancer Res 2006;47:abstract 4855
40. Kefford R, Arkenau H, Brown MP, et al. Phase I/II study of GSK2118436, aselective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 2010;28(15 Suppl):abstract 8503
41. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26(13):2139-46
42. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439(7074):358-62
43. Emery CM, Vijayendran KG, Zipser MC, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci USA 2009;106(48):20411-16
44. Montagut C, Sharma SV, Shioda T, et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008;68(12):4853-61
45. Paraiso KH, Fedorenko IV, Cantini LP, et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br J Cancer 2010;102(12):1724-30
46. Infante JR, Fecher LA, Nallapareddy S, et al. Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212. J Clin Oncol 2010;28:7s(Suppl):abstract 2503
47. Bollag G, Hirth P, Tsai J, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma NatureYear published: (2010) DOI: doi:10.1038/nature09454; Sept 7 epub
48. Tsai J, Lee JT, Wang W, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA 2008;105(8):3041-6
49. Khazak V, Astsaturov I, Serebriiskii IG, Golemis EA. Selective Raf inhibition in cancer therapy. Expert Opin Ther Targets 2007;11(12):1587-609
50. Smalley KS. PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs 2010;11(6):699-706
51. Tsai J, Zhang J, Bremer R, et al. Development of a novel inhibitor of oncongenic B-Raf. Proc Am Assoc Cancer Res 2006;47(507):abstract 2412
52. Sondergaard JN, Nazarian R, Wang Q, et al. Differential sensitivity of melanoma cell lines with BRAFV600E mutation to the specific Raf inhibitor PLX4032. J Transl Med 2010;8:39
53. Lee JTK, Smalley K, Tsai J, et al. Anti-tumor activity of PLX4032, a novel BRaf V600E inhibitor. EJC Suppl 2006;4(12):569
54. Su F, Yang HI, Higgin B, et al. PLX4032, a selective beta-raf V600E inhibitor has potent anti-tumor activity in beta-raf V600E-bearing colorectal xenografts and shows additive effect with other chemoagents. AACR-NCI-EORTC Int Congress 2007;23:abstract 252
55. Hersey P, Zhang X, Jiang C. Induction of apoptosis in human melanoma by the BRAF inhibitor PLX4032: the key to therapeutic success? J Clin Oncol 2010;28(7 Suppl):abstract 8559
56. Halaban R, Zhang W, Bacchiocchi A, et al. PLX4032, a selective BRAF (V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment Cell Melanoma Res 2010;23(2):190-200
57. Joseph D, Poulikakos PI, Pratilas CA, et al. PLX4032, a selective inhibitor of RAF kinase activity, inhibits BRAF V600E tumor proliferation and MAPK signaling in vitro and in vivo. Am Assoc Cancer Res Ann Meeting 2008;99th:abstract 3437
58. Kaplan FM, Shao Y, Mayberry MM, Aplin AE. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene, [6 September 2010] doi:10.1038/onc.2010.40 epub
59. Montecillo ML, Sondergaard J, Ribas A. Antitumor activity of B-RAF inhibitor (PLX4032) against a panel of human melanoma cell lines. J Invest Med 2009;57(1 Suppl):abstract 403
60. Kolinsky K, Bollag G, Lee R, et al. Antitumor activitiy of PLX4032, a selective V600E B-Raf inhibitor, as monotherapy and in combination with capecitabine + bevacizumab in a colorectal cancer xenograft model. EJC Suppl 2008;6(Suppl 12):185
61. Kolinsky K, Su F, Bollag G, et al. Efficacy of PLX4032, a selective V600E B-Raf inhibitor, as monotherapy in combination with capecitabine +/-bevacizumab in a colorectal xenograft model. Gastrointestinal Cancers Symp 2009;abstract 362
62. Nolop K, Jones WB, Tsai J, et al. Discovery and pre-clinical development of a novel inhibitor of oncogenic B-Raf. J Clin Oncol 2006;24(Suppl 18S):abstract 13056
63. Spevak W, Cho H, Shi S, et al. Discovery and optimization of a selective inhibitor of oncogenic B-Raf. Am Chem Soc Natl Meet Exposition 2009;237th(MEDI 086). Available from: http://wiz2.pharm.wayne.edu/mediabstracts2009.pdf
64. Flaherty K, Puzanov I, Kim KB, et al. "Inhibition of mutated, activated BRAF in metastatic melanoma" NEJM 2010;363(9):809-19
65. Rubinstein JC, Sznol M, PavlickAC, et al. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 2010;8:67
66. McArthur G, Puzanov I, Ribas A, et al. Early FDG-PET responses to PLX4032 in BRAF-mutant advanced melanoma. J Clin Oncol 2010;28(7 Suppl):abstract 8529
67. Heidorn SJ, Milagre C, Whittaker S, et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010;140(2):209-21
68. Hatzivassiliou G, Song K, Yen I, et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010;464(7287):431-5
69. Poulikakos PI, Zhang C, Bollag G, et al. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010;464(7287):427-31
70. Cichowski K, Janne PA. Drug discovery: inhibitors that activate. Nature 2010;464(7287):358-9
71. Lacouture ME, McArthur G, Chapman PB, et al. PLX4032 (RG7204), a selective mutant RAF inhibitor: clinical and histological characteristics of therapy-associated cutaneous neoplasms in a phase I trial. J Clin Oncol 2010;28(7 Suppl):abstract 8592
72. Arnault JP, Wechsler J, Escudier B, et al. Keratoacanthomas and squamous cell carcinomas in patients receiving sorafenib. J Clin Oncol 2009;27(23):e59-61
73. Pratilas CA, Solit DB. Targeting the MAPK pathway: physiological feedback and drug response. Clin Cancer Res 2010;16(13):3329-34
74. Spencer JM, Kahn SM, Jiang W, et al. Activated ras genes occur in human actinic keratoses, premalignant precursors to squamous cell carcinomas. Arch Dermatol 1995;131(7):796-800
75. Mateus C, Arnault J, Tomasic G, et al. Activation of the MAP-kinase pathway in the skin of patients treated with sorafenib: clinical and molecular characterization of skin tumors associated with the multikinase inhibitor sorafenib. J Clin Oncol 2010;28(7 Suppl):abstract 9130 Further insight into the development of keratoacanthomas and squamous cell carcinomas in patients with PLX4032 treatment.
76. Smalley KS, Nathanson KL, Flaherty KT. Genetic subgrouping of melanoma reveals new opportunities for targeted therapy. Cancer Res 2009;69(8):3241-4
77. Flaherty KT, Smalley KS. Preclinical and clinical development of targeted therapy in melanoma: attention to schedule. Pigment Cell Melanoma Res 2009;22(5):529-31